Engflag

Ark

Quick links to important sections

Ark

Ark_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ark

Property Description
Active ingredient Diclofenac (Sodium/Potassium salt)
Form Tablets, Injections, Suppositories, Topical Gels/Solutions
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General purpose Pain relief, inflammation reduction, fever reduction
Origin Synthetic Phenylacetic acid derivative

What Type of Medicine is Ark? (Identity and Classification)

Ark is a trade name for a medicinal product that contains the active ingredient Diclofenac, which belongs to the widely used pharmacological class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This compound is chemically defined as a synthetic Phenylacetic acid derivative, setting it apart from other NSAID groups like the propionic acids. The classification confirms that the medicine is fundamentally designed to intervene in the body's inflammatory and pain signaling pathways.

Composition and Available Forms of Ark

The core composition of Ark is the single active substance, Diclofenac, typically utilized as either the sodium or potassium salt. As a monotherapy product, the drug's effects are solely due to the Diclofenac component. The medicine is manufactured in various dosage forms, including conventional and sustained-release tablets, solutions for injection, and various topical preparations such as gels. This versatility allows the drug to be administered through oral, parenteral, rectal, and cutaneous routes, characteristic of a widely established therapeutic agent.

General Purpose and Mechanism of Action

The central purpose of Ark is to deliver integrated relief by addressing the three primary characteristics of inflammatory states: pain, swelling, and elevated body temperature. Diclofenac achieves this by acting as a powerful inhibitor of the Cyclooxygenase (COX) enzymes. By blocking this enzymatic action, the drug prevents the production of prostaglandins, which are the essential chemical messengers that signal pain and drive the inflammatory cascade. This defining anti-prostaglandin action is the core reason the medicine is categorized for symptomatic relief.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Ark?

Possible Side Effects and Safety Information for Ark

The safety profile of Ark is formally established through rigorous regulatory review of clinical trial data and post-market surveillance. All documented adverse reactions and safety restrictions are compiled from official governmental regulatory documents, such as the FDA-approved prescribing information or the EMA Summary of Product Characteristics.

Adverse Reaction Profile

Adverse reactions are classified by both their system-organ class (SOC) and frequency, adhering to standard regulatory frameworks (e.g., ICH/CIOMS frequency bands).

Classification Example Categories (Placeholder)
Very Common (ge 1/10) Reactions frequently reported during clinical trials, such as headache, fatigue, or mild gastrointestinal upset.
Common (ge 1/100 to < 1/10) Adverse effects observed with moderate frequency, often involving the nervous system or skin.
Serious & Clinically Significant Events like severe hypersensitivity reactions, organ toxicity (e.g., hepatic or renal impairment), or hematologic abnormalities that are documented in the 'Warnings and Precautions' section.

Safety Considerations and Restrictions

Safety data addresses potential risks across various patient groups and usage contexts. Official regulatory documents include restrictions to ensure safe use.

  • Population-Specific Concerns: Special caution or monitoring is typically required for specific patient groups, such as those with pre-existing hepatic or renal impairment, or in pediatric or geriatric patients, as risk/benefit considerations may vary.
  • Dose- or Exposure-Related Patterns: Increases in the incidence or severity of certain adverse reactions may be explicitly noted to correlate with higher doses or prolonged exposure to Ark.
  • Safety-Related Limitations: Use is formally contraindicated in patients with specific hypersensitivities or co-existing conditions that increase risk. Mandatory safety monitoring, such as regular laboratory testing for specific markers, may be required by the regulatory authority.

Official Regulatory Summary

Regulatory safety information structures the understanding of risks by categorizing adverse events and defining limitations. This includes a summary of the overall adverse reaction profile, highlighting the necessity for specific patient monitoring and adherence to documented contraindications. The official label provides the comprehensive, non-promotional basis for understanding the known risks and constraints of using this medicine.

Overdose and Emergency Response

The official regulatory documents state that an overdose with Ark (Diclofenac) requires immediate emergency medical attention. The clinical presentation primarily involves the gastrointestinal and nervous systems. Documented manifestations include nausea, vomiting, epigastric pain, and potential gastrointestinal hemorrhage (bleeding). Central nervous system effects officially noted include headache, dizziness, somnolence, and tinnitus. Severe, life-threatening outcomes can include acute renal failure, liver damage (hepatotoxicity), and profound CNS effects like convulsions or coma. Cardiovascular collapse and respiratory depression are also documented as possible complications in cases of massive overdose.

Anyone suspecting an overdose must contact a Poison Control Center or emergency services right away. Due to the absence of a specific neutralizing agent, no specific antidote is known for Diclofenac overdose. Regulator-mandated intervention is thus limited to symptomatic and supportive treatment. In hospital settings, close medical monitoring is required, particularly of renal and hepatic function and prothrombin time. Special consideration is given to patients with pre-existing organ impairment or the elderly, who are identified as being at higher risk for severe toxicity.

Therapeutic Uses of Ark

What Ark Treats: Main Uses and Benefits

Ark is a medication used in situations involving certain distressing symptoms, providing supportive therapeutic benefit that helps ease the overall burden of symptoms. Its therapeutic applications are aligned with domains involving heightened symptom expression, particularly where inflammation, pain, or fever are key issues, offering symptomatic relief across key domains. Ark (Diclofenac) is commonly used to help with pain management, tenderness, swelling, and stiffness caused by various forms of arthritis and is also applied for conditions like migraine headaches and painful menstrual periods.

The medication is relevant in contexts involving increased systemic discomfort, applied during phases of increased distress or discomfort following surgical procedures, or is used for managing acute episodes like Gout attacks. It may also assist with symptoms related to inflammatory states in chronic conditions such as Rheumatoid Arthritis and Osteoarthritis.

“It is applied across domains where additional symptomatic support may be needed, contributes to easing discomfort during periods of heightened symptoms.”

Quick Fact: Symptom Support for Inflammation and Pain

This medication is commonly used to help with symptom clusters that may become intense or disruptive in conditions characterized by periods of heightened symptoms, supporting the patient by easing discomfort and may assist with maintaining functional stability.

Regulatory References

  1. Diclofenac: MedlinePlus Drug Information

Eligibility and Restrictions for Use

This section outlines the official, regulatory-defined eligibility and non-eligibility for systemic Ark (diclofenac), based on documentation from authorities like the FDA and EMA.

Eligibility Scope

Category Official Regulatory Status
Populations for whom use is allowed Generally Adults (18 years and older) for most systemic formulations. Pediatric use is generally not established for those under 18.
Populations for whom use is contraindicated Patients with a history of asthma, hives, or allergic reactions after taking aspirin or any other NSAID. Individuals with active GI bleeding or peptic ulceration. Patients undergoing Coronary Artery Bypass Graft (CABG) surgery. Patients with established Congestive Heart Failure (NYHA Class II-IV), Ischaemic Heart Disease, Peripheral Arterial Disease, or Cerebrovascular Disease (EMA/MHRA restriction).
Pregnancy and Lactation Eligibility Contraindicated in pregnancy starting at 30 weeks gestation; use should be avoided from 20 weeks gestation. Use during lactation requires caution and risk assessment.
Eligibility-Related Restrictions Avoid use in patients with advanced renal disease or recent Myocardial Infarction (MI) unless benefits outweigh the risks. Use requires careful consideration in the elderly and those with significant cardiovascular risk factors.

Connection to the overall eligibility profile: Regulatory documents establish clear absolute contraindications based on specific, high-risk pre-existing conditions (e.g., severe cardiac disease, active GI issues) and known hypersensitivity to NSAIDs. Conditional use warnings apply to populations with elevated systemic risks, such as advanced kidney disease or late-stage pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ark’s interaction profile is strictly defined by regulatory authorities concerning both pharmacokinetic and pharmacodynamic interactions with co-administered medicines and products.

The medicine is formally contraindicated for the treatment of pain in the setting of perioperative coronary artery bypass graft (CABG) surgery. Due to the high risk of serious gastrointestinal bleeding, co-administration with Aspirin (at analgesic doses) is not generally recommended, and concurrent use with other systemic NSAIDs should be avoided.

Documented pharmacokinetic interactions show that co-administration with CYP inhibitors, such as Voriconazole, significantly increases Diclofenac’s plasma exposure. Conversely, Diclofenac can affect the clearance of other drugs; for example, it may elevate Lithium plasma concentrations.

Significant pharmacodynamic interactions exist with Anticoagulants (like Warfarin) and other anti-hemostatic drugs, which carries a synergistic risk of bleeding. Furthermore, co-administration with ACE inhibitors, ARBs, or Diuretics may diminish the blood pressure or fluid-clearing effects of those medicines. This renal function risk is noted to be greater in patients who are elderly, volume-depleted, or have pre-existing renal impairment. For oral forms, food is documented to delay the time to peak plasma concentration, though it does not affect the overall extent of absorption. The topical formulation requires the treated area not be washed for at least one hour after application.

Mechanism of Action

The physiological effects of Ark (Diclofenac) are rooted in its precise intervention in the Cyclooxygenase ( COX) enzyme system, which controls the body's synthesis of inflammatory mediators.

Inhibition of Prostaglandin Synthesis

The drug's primary action is the non-selective and reversible inhibition of both Cyclooxygenase-1 ( COX-1) and Cyclooxygenase-2 ( COX-2) enzymes. This core mechanistic domain affects the Arachidonic Acid Cascade, blocking the conversion of arachidonic acid into prostanoids and resulting in a reduction in PGE2 synthesis, which are central drivers of local inflammation and nociceptive signaling.

Modulation of Nociceptive and Thermoregulatory Signaling

The reduction in PGE2 levels influences two major systemic processes: In the periphery, it dampens the sensitization of nociceptors (pain receptors), thereby decreasing afferent input from sensitized nociceptors. Simultaneously, in the central nervous system, this mechanism achieves a central thermoregulatory adjustment by resetting the PGE2-elevated set-point in the hypothalamus, facilitating the reset of the central thermoregulatory set-point.

Mechanistic Limitations

The action addresses only the effects mediated by prostanoids and other downstream factors. The drug's action does not modify the underlying disease progression and its mechanism is constrained in scenarios where physiological responses are driven by signaling pathways independent of prostaglandin activity.

Dosage and Administration Information

How to Use Ark (Official Administration Guidelines)

The administration of Ark (Diclofenac) is strictly governed by documentation to ensure consistent and proper use. The central instruction across all forms is to use the lowest effective dose for the shortest duration possible, consistent with individual patient treatment goals.

Approved Dosing and Routes

Ark is approved for use via multiple routes, with specific instructions for each:

  • Oral: Available as immediate-release, delayed-release, and extended-release tablets/capsules. Standard adult systemic dosing often ranges from 50 mg to 75 mg per dose, with a maximum systemic daily dose typically limited to 150 mg.
  • Topical: Applied to the skin as a gel or solution. Specific application techniques, such as using a dosing card for the gel or applying drops to the knee, are provided in the labeling.
  • Parenteral/Rectal: Also available in formulations for intravenous (IV) injection and rectal suppositories, typically administered in a controlled setting.

Administration Requirements

Administration Rule Official Guideline
Dose Integrity Enteric-coated/extended-release forms must be swallowed whole; they should not be crushed, split, or chewed, as this compromises the drug's intended release profile.
Oral Timing Standard oral tablets may be taken with food. However, the specialized oral powder for solution must be mixed only with 1 to 2 ounces (30 to 60 mL) of water and taken on an empty stomach to ensure rapid absorption.
Frequency Dosing schedules are typically once, twice, or three times daily, depending on the formulation and indication. Topical applications may be applied up to four times daily.
Specific Populations Older adults should commence treatment using the lowest effective dose for the shortest time. Pediatric dosing is weight-based and determined by the prescriber.
Missed Dose If a dose is missed, instructions advise skipping the missed dose and resuming the regular schedule. A double dose should not be taken.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ark

Evidence for Use in Osteoarthritis (OA) and Joint Pain

Research exploring symptoms related to Osteoarthritis (OA) and joint pain has primarily used short-term randomized controlled trials (RCTs) for both oral and topical forms. These studies examined measures related to physical comfort and daily activity level, such as monitoring pain intensity scores in adults and older adults. Findings report how symptoms evolved in the observed populations, typically over defined time intervals of up to 12 weeks. Long-term outcomes (beyond one year) are not fully characterized in large, controlled trials, and evidence quality varies due to differences in older study designs.

Evidence for Use in Inflammatory Conditions (RA and AS)

Ark was evaluated in research settings related to Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS), utilizing short-term RCTs and long-term observational studies. These studies monitored measures related to inflammatory states, focusing on changes in joint swelling, tenderness, and disease activity scores. Follow-up durations were limited in the controlled setting; thus, most symptomatic outcomes are based on short-term studies. Long-term effects are not fully established through controlled comparisons against all alternative treatments.

Studies on Long-Term Follow-up and Uncertainty

Evidence for long-term use in chronic conditions relies on a mix of intermediate-term RCTs (typically up to 12 weeks) and real-world observational data. This means that long-term effects are not fully established through randomized, controlled studies designed specifically to assess measures related to daily functioning over multiple years. Data for certain groups, such as pediatric populations or those with specific high-risk pre-existing conditions, remains insufficient or uncertain. Research highlights that evidence quality varies across studies, and findings reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Ark (FAQ)

Q: How long does it typically take to notice the effects of Ark?

A: Official prescribing information indicates that the time until the medicine's effects are noticeable can vary depending on the form used. For some oral forms, relief has been reported as early as 30 minutes. Topical gel forms typically show an effect within a few hours.

Q: Does Ark interact with common pain relievers like ibuprofen?

A: Regulatory documents explicitly advise against the concurrent use of Ark with other systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes ibuprofen. Combining these medicines is associated with a heightened risk of serious adverse effects, including risks to the gastrointestinal tract.

Q: What makes Ark different from other drugs in its class?

A: Ark is chemically classified as a phenylacetic acid derivative, distinguishing it from other NSAID chemical families. Its mechanism of action involves a degree of selectivity in inhibiting the COX-2 enzyme. Furthermore, certain formulations are noted for a fast absorption rate, which can lead to a rapid onset of pain relief.

Q: Do I need to change my diet while using Ark?

A: Official administration guidelines state that certain oral forms are directed to be taken on an empty stomach to ensure rapid absorption. In addition, the oral powder solution is directed to be mixed only with water and should not be mixed with any other liquid.

Q: Is Ark known to affect sleep patterns?

A: Regulatory safety data includes reports of effects on the nervous system that may impact sleep. These reported effects include both insomnia (difficulty sleeping) and drowsiness.

Q: How quickly does Ark leave the body?

A: The pharmacokinetic information in official prescribing documents states that the drug's elimination half-life is short, typically ranging from 1.2 to 2 hours. This half-life represents the time it takes for half of the medicine to be eliminated from the body.

Q: Is it normal to experience a headache when beginning Ark?

A: Regulatory safety data classifies headache as a 'very common' adverse reaction, meaning it is reported in a high percentage of patients during clinical trials. This classification suggests that experiencing a headache when starting the medicine is a frequently reported event during clinical studies.

Q: What information is available about Ark's use during pregnancy or breastfeeding?

A: Official documents indicate that the use of this medicine is contraindicated in the third trimester of pregnancy, starting at 30 weeks gestation. For breastfeeding, official information advises caution, and the risk versus benefit is subject to assessment by a healthcare professional.

Q: Is Ark in the same class of medicines as [similar drug name]?

A: Ark belongs to the pharmacological class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This classification includes many similar medicines that function by reducing inflammation and pain.

Q: Can Ark be taken by elderly people?

A: Regulatory information indicates that use in the elderly has not shown age-specific problems that would prevent its usefulness. However, official information notes that caution and closer monitoring are generally advised for older adults due to the increased risk of age-related conditions, especially cardiovascular and renal issues.

Q: What are the most common general side effects reported for Ark?

A: The most common adverse reactions, reported in 1 to 10 out of 100 people, are often mild in nature. These frequently reported side effects include headache, dizziness, mild gastrointestinal upset, and nausea.

Q: Are there any known issues with taking Ark with vitamins or supplements?

A: Official prescribing information advises caution when using Ark alongside any product, including certain supplements, that may increase the risk of bleeding or affect the drug's metabolism. Consultation with a healthcare professional regarding all supplements used is advised by regulatory sources.

Q: Is Ark considered a long-term treatment option?

A: Official guidelines emphasize that this medicine should be used for the shortest duration necessary to achieve treatment goals. Therefore, it is typically prescribed for defined periods of use rather than indefinite, long-term maintenance therapy.

Q: What kind of studies support the use of Ark?

A: The use of Ark is supported by various clinical studies detailed in official documentation. These include short-term, randomized controlled trials (RCTs) used to demonstrate efficacy, as well as longer-term observational data.

Q: Is Ark approved in other countries besides the US?

A: Diclofenac, the active ingredient in Ark, is a globally recognized medicine. It has received marketing authorization from multiple major regulatory authorities, including those in Europe, Australia, and Canada.

Q: What is the function of the inactive ingredients in Ark?

A: Inactive ingredients are components added to the formulation that do not have therapeutic activity. They serve various technical purposes, such as controlling the color, taste, stability, or the rate at which the active medicine is released into the body (like an enteric coating).

Q: Can Ark be taken with antacids?

A: Some official patient information suggests that antacids may be taken with the medicine, if needed, to help relieve stomach pain. However, this may slow the medicine's absorption. The official labeling outlines specific restrictions, particularly regarding certain types of antacids, such as those containing magnesium.

Q: Do people generally tolerate Ark well?

A: Safety data indicates that the most commonly reported side effects are categorized as Common or Very Common. While serious adverse events are highlighted in warnings, the overall safety profile details frequent but generally mild side effects.

Q: Is Ark known to interact with herbal remedies like St. John's Wort?

A: Official prescribing information advises caution regarding products, including herbal remedies, that may affect the drug’s metabolism or increase the risk of bleeding. The disclosure of all supplements to a healthcare professional is consistent with official guidance.

Q: Does Ark affect a person's ability to concentrate?

A: Adverse event information for the drug includes reports of nervous system effects. These can include dizziness, confusion, and drowsiness, which may potentially impact a person's ability to concentrate.

Q: How is the safety of Ark monitored after it is approved?

A: The safety of Ark is continuously monitored by regulatory authorities through official post-market surveillance systems, which collect and evaluate reports of adverse events after the medicine has been approved and released to the public.

Q: Is Ark known to cause weight changes?

A: Regulatory safety information lists fluid retention, or edema, as a common side effect of the medicine. This fluid retention may potentially result in weight gain.

Q: Is Ark considered a maintenance treatment?

A: Official prescribing information advises using the medicine for the shortest duration necessary. This guidance means it is typically prescribed for defined periods of use rather than indefinite maintenance therapy.

Q: What is the purpose of the different strengths of Ark?

A: Different strengths of the medicine are made available to allow healthcare providers to select the lowest effective dose for the shortest duration possible, tailored to the individual patient’s condition and treatment goals.

Q: Does Ark have a warning about driving or operating machinery?

A: Official safety information advises exercising caution and avoiding driving or operating machinery if side effects such as dizziness or drowsiness are experienced, as these effects can impair ability.

Q: Has Ark been studied in children or adolescents?

A: Yes, some systemic and topical formulations of the medicine have dosing guidelines established for use in pediatric patients (children and adolescents). This dosing is typically based on age or weight, depending on the specific product and country of approval.

Q: What is the shelf life of Ark?

A: The shelf life of the medicine is indicated by the expiration date printed on the packaging. This date represents the time until which the manufacturer guarantees the safety and full potency of the product when stored correctly.

Q: Are there any foods or drinks that should be avoided while on Ark?

A: Regulatory safety information includes warnings about the concurrent use of alcohol, as this may significantly increase the risk of gastrointestinal bleeding. Additionally, certain oral forms are directed to be mixed only with water.

Q: Does Ark cause a feeling of dependency or withdrawal when stopped?

A: Official prescribing information does not list the medicine as a controlled substance. It also does not document or warn of symptoms related to physical dependence or withdrawal upon discontinuation.

Q: Are the side effects of Ark usually mild or severe?

A: The medicine is associated with common side effects that are often mild in nature. However, official warnings highlight the potential for rare but serious adverse events involving the cardiovascular, gastrointestinal, or renal systems.

How should Ark be stored and disposed of?

How to Store and Dispose of Ark (Diclofenac)

The storage and disposal of Ark must strictly adhere to regulatory labeling to maintain product quality and safety.

Storage Requirements

Oral tablets and topical gels require storage at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be kept away from excess moisture and heat, and the topical gel must be protected from freezing. All forms must be kept in a closed container and stored out of the reach of children and pets.

Disposal Instructions

Expired or unused portions of the medicine should be disposed of using a drug take-back program or authorized collection sites. Regulatory guidance generally advises against flushing Diclofenac down the toilet. For specific forms, such as topical patches, the patches must be folded sticky-sides together before disposal to minimize exposure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ark found in:

A-Z Index: